Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,954
  • Shares Outstanding, K 52,635
  • Annual Sales, $ 82,000 K
  • Annual Income, $ -50,920 K
  • 60-Month Beta 0.75
  • Price/Sales 1.24
  • Price/Cash Flow N/A
  • Price/Book 0.53
Trade JNCE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.97
  • Most Recent Earnings $-0.60 on 11/10/22
  • Next Earnings Date 05/04/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.72
  • Number of Estimates 1
  • High Estimate -0.72
  • Low Estimate -0.72
  • Prior Year -0.72
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8400 +2.17%
on 04/04/23
1.9800 -5.05%
on 04/17/23
+0.0300 (+1.62%)
since 04/03/23
3-Month
0.8957 +109.89%
on 03/10/23
1.9800 -5.05%
on 04/17/23
+0.6700 (+55.37%)
since 02/03/23
52-Week
0.5773 +225.65%
on 12/13/22
5.8700 -67.97%
on 05/06/22
-3.2300 (-63.21%)
since 05/03/22

Most Recent Stories

More News
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics

Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article.

NKTR : 1.1700 (-6.40%)
CPRX : 15.05 (-0.07%)
KALV : 12.07 (-1.55%)
JNCE : 1.8800 (-2.59%)
LRMR : 9.31 (-0.85%)
5 Stocks to Buy as the Drug Industry Rebounds in 2023

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio.

CPRX : 15.05 (-0.07%)
NKTR : 1.1700 (-6.40%)
KALV : 12.07 (-1.55%)
JNCE : 1.8800 (-2.59%)
LRMR : 9.31 (-0.85%)
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

CRSP : 63.11 (-0.71%)
JNCE : 1.8800 (-2.59%)
CERT : 14.89 (+1.71%)
EQRX : 2.34 (-2.09%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVT, USX, JNCE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CVT : 8.52 (+0.24%)
USX : 6.14 (unch)
JNCE : 1.8800 (-2.59%)
JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Jounce Therapeutics, Inc. (NASDAQ: JNCE) to Concentra Biosciences, LLC for $1.85 in cash per share plus a non-tradeable...

JNCE : 1.8800 (-2.59%)
Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

JNCE : 1.8800 (-2.59%)
USX : 6.14 (unch)
INDT : 66.99 (+0.01%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

JNCE : 1.8800 (-2.59%)
ADAP : 1.0200 (+0.99%)
TCRR : 1.4800 (-5.73%)
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences

Jounce Therapeutics (JNCE) receives a proposal from Concentra Biosciences to acquire 100% equity stake in the company.

ADPT : 3.13 (-5.15%)
CRSP : 63.11 (-0.71%)
JNCE : 1.8800 (-2.59%)
EQRX : 2.34 (-2.09%)
S&P Futures Plunge Ahead of Key U.S. PPI and Retail Sales Data

March S&P 500 futures (ESH23) are trending down -1.02% this morning after three major U.S. benchmark indices finished the regular session higher as bank shares rebounded and key U.S. inflation data met...

ESH23 : 3,957.05s (-0.09%)
UBER : 69.90 (-0.23%)
DASH : 111.80 (-0.22%)
META : 502.10 (-0.41%)
BOL.FP : 5.710 (-0.52%)
HMB.S.DX : 188.225 (+0.01%)
JNCE : 1.8800 (-2.59%)
DCPH : 25.59 (+0.08%)
VCSA : 4.40 (+1.38%)
S : 18.36 (-0.54%)
FRPT : 124.37 (-0.65%)
SCHW : 73.25 (unch)
INVESTIGATION ALERT: Halper Sadeh LLC Investigates INDT, FOCS, JNCE, PTRS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

INDT : 66.99 (+0.01%)
FOCS : 52.99 (-0.02%)
JNCE : 1.8800 (-2.59%)
PTRS : 7.15 (+0.99%)

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

3rd Resistance Point 1.9633
2nd Resistance Point 1.9467
1st Resistance Point 1.9133
Last Price 1.8800
1st Support Level 1.8633
2nd Support Level 1.8467
3rd Support Level 1.8133

See More

52-Week High 5.8700
Fibonacci 61.8% 3.8482
Fibonacci 50% 3.2236
Fibonacci 38.2% 2.5991
Last Price 1.8800
52-Week Low 0.5773

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar